JP2012512158A5 - - Google Patents

Download PDF

Info

Publication number
JP2012512158A5
JP2012512158A5 JP2011540809A JP2011540809A JP2012512158A5 JP 2012512158 A5 JP2012512158 A5 JP 2012512158A5 JP 2011540809 A JP2011540809 A JP 2011540809A JP 2011540809 A JP2011540809 A JP 2011540809A JP 2012512158 A5 JP2012512158 A5 JP 2012512158A5
Authority
JP
Japan
Prior art keywords
methyl
compound according
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011540809A
Other languages
English (en)
Japanese (ja)
Other versions
JP5509217B2 (ja
JP2012512158A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/067056 external-priority patent/WO2010074947A1/en
Publication of JP2012512158A publication Critical patent/JP2012512158A/ja
Publication of JP2012512158A5 publication Critical patent/JP2012512158A5/ja
Application granted granted Critical
Publication of JP5509217B2 publication Critical patent/JP5509217B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011540809A 2008-12-16 2009-12-08 アミノピラゾール化合物 Expired - Fee Related JP5509217B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16
US61/122,854 2008-12-16
PCT/US2009/067056 WO2010074947A1 (en) 2008-12-16 2009-12-08 Amino pyrazole compound

Publications (3)

Publication Number Publication Date
JP2012512158A JP2012512158A (ja) 2012-05-31
JP2012512158A5 true JP2012512158A5 (enExample) 2013-01-24
JP5509217B2 JP5509217B2 (ja) 2014-06-04

Family

ID=41630090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540809A Expired - Fee Related JP5509217B2 (ja) 2008-12-16 2009-12-08 アミノピラゾール化合物

Country Status (38)

Country Link
US (2) US20100286139A1 (enExample)
EP (1) EP2379557B1 (enExample)
JP (1) JP5509217B2 (enExample)
KR (1) KR101300458B1 (enExample)
CN (1) CN102232075B (enExample)
AR (1) AR074240A1 (enExample)
AU (1) AU2009330503B2 (enExample)
BR (1) BRPI0923048A2 (enExample)
CA (1) CA2744714C (enExample)
CL (1) CL2011001445A1 (enExample)
CO (1) CO6331442A2 (enExample)
CR (1) CR20110341A (enExample)
CY (1) CY1113637T1 (enExample)
DK (1) DK2379557T3 (enExample)
DO (1) DOP2011000190A (enExample)
EA (1) EA019554B1 (enExample)
EC (1) ECSP11011132A (enExample)
ES (1) ES2396617T3 (enExample)
HN (1) HN2011001697A (enExample)
HR (1) HRP20120918T1 (enExample)
IL (1) IL213065A0 (enExample)
JO (1) JO2833B1 (enExample)
MA (1) MA32900B1 (enExample)
MX (1) MX2011006441A (enExample)
MY (1) MY158691A (enExample)
NZ (1) NZ592641A (enExample)
PA (1) PA8851101A1 (enExample)
PE (1) PE20110549A1 (enExample)
PL (1) PL2379557T3 (enExample)
PT (1) PT2379557E (enExample)
SG (1) SG172202A1 (enExample)
SI (1) SI2379557T1 (enExample)
SV (1) SV2011003949A (enExample)
TN (1) TN2011000292A1 (enExample)
TW (1) TWI440640B (enExample)
UA (1) UA104743C2 (enExample)
WO (1) WO2010074947A1 (enExample)
ZA (1) ZA201103942B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
KR20130131461A (ko) * 2011-03-07 2013-12-03 폰다지오네 텔레톤 Tfeb 변종 및 그의 용도
PH12013502530A1 (en) * 2011-06-15 2014-01-27 Life And Brain Gmbh Glioblastoma inhibiting compounds and their use
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
RS63364B1 (sr) 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
SMT202100674T1 (it) 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
US11299494B2 (en) * 2016-11-17 2022-04-12 Bristol-Myers Squibb Company Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
CA2467718C (en) 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
KR20070104936A (ko) 2005-02-16 2007-10-29 아스트라제네카 아베 화합물
KR101362621B1 (ko) 2005-02-16 2014-02-13 아스트라제네카 아베 화합물
BRPI0613501A2 (pt) * 2005-07-01 2011-01-11 Irm Llc composto, composição farmacêutica e uso do mesmo
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
PE20070543A1 (es) * 2005-10-06 2007-06-14 Schering Corp Pirazolopirimidinas como inhibidores de protein quinasas
CN101321759A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
BRPI0718266A2 (pt) * 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
CN101679429A (zh) * 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途
MX2009012612A (es) 2007-05-23 2009-12-07 Pharmacopeia Llc Purinonas e inhibidores 1h-imidazopiridinonas como pkc-theta.
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Similar Documents

Publication Publication Date Title
HRP20120918T1 (hr) Aminopirazolski spoj
HRP20161674T1 (hr) 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE
RU2018102080A (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2014511893A5 (enExample)
JP2014521735A5 (enExample)
IL196854A (en) Indole compounds and their appropriate pharmaceutical salts and their use in the preparation of @ drugs
WO2009088414A3 (en) Oral pharmaceutical dosage forms
IL206500A0 (en) Process for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
JP2010536849A5 (enExample)
EP2179291A4 (en) ARZNEISTOFFAUSWAHL FÜR LUNGSKREBSTHERAPIE USING ARRAYS ON ANTIBODY BASIS
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP2012524089A5 (enExample)
UA115320C2 (uk) Інгібітори кінази
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
WO2009007749A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
IL196470A0 (en) Antagonist antibody against epha2 for the treatment of cancer
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MY191934A (en) Macrocyclic compounds as trk kinase inhibitors
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
IL183383A0 (en) Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
JP2012508240A5 (enExample)